文献速递慢性肾脏病遗传性与小管间质肾病

线粒体功能障碍与线粒体自噬阻滞参与慢性肾脏病-矿物质骨异常中的肾性骨营养不良

Mitochondrial dysfunction and mitophagy blockade contribute to renal osteodystrophy in chronic kidney disease-mineral bone disorder.
PubMed 文献 · Kidney Int · 2025-02-06

本研究探讨慢性肾脏病-矿物质骨异常(CKD-MBD)小鼠模型中骨细胞线粒体自噬停滞是否导致骨丢失。RNA-seq显示CKD-MBD小鼠胫骨线粒体自噬及线粒体功能相关基因表达改变,mito-QC报告小鼠中骨细胞线粒体自噬溶酶体增加2-3倍。尿毒症毒素处理成骨细胞导致线粒体自噬溶酶体增多、线粒体形态扭曲、膜电位和氧化磷酸化降低、氧自由基产生增加,雷帕霉素可逆转。线粒体靶向抗氧化剂MitoQ和炭吸附剂AST-120可减轻尿毒症毒素诱导的线粒体改变并改善骨健康。

要点

  • CKD-MBD小鼠骨细胞线粒体自噬功能受损,线粒体自噬溶酶体增加但清除效率下降。
  • 尿毒症毒素可诱导体外成骨细胞线粒体功能障碍和线粒体自噬 machinery 损伤,雷帕霉素可逆转。
  • MitoQ和AST-120可减轻尿毒症毒素诱导的线粒体改变并改善骨健康,提示靶向线粒体自噬或为干预途径。

核心结论

  • 受损线粒体清除障碍可能参与肾性骨营养不良表型,靶向尿毒症毒素、氧自由基产生和线粒体自噬过程或为保护CKD-MBD患者骨健康的新干预途径。

研究设计与样本

  • 研究采用CKD-MBD小鼠模型进行RNA-seq分析,并使用mito-QC报告小鼠观察骨细胞线粒体自噬溶酶体。
  • 体外实验用尿毒症毒素处理培养成骨细胞,并测试雷帕霉素、MitoQ和AST-120的干预效果。

主要发现

  • RNA-seq显示CKD-MBD小鼠胫骨中线粒体自噬和线粒体功能相关基因表达改变,p62/SQSTM1、ATG7和LC3表达与功能性线粒体自噬不一致。
  • 在伴有ROD的mito-QC报告小鼠中,骨细胞线粒体自噬溶酶体增加2-3倍。
  • 尿毒症毒素处理成骨细胞后线粒体自噬溶酶体数量增加、线粒体形态扭曲,膜电位和氧化磷酸化降低,氧自由基产生增加,p62/SQSTM1和LC3-II表达改变与线粒体自噬 machinery 受损一致。
  • 雷帕霉素可逆转尿毒症毒素对p62/SQSTM1和LC3-II表达的影响。
  • MitoQ和AST-120能减轻尿毒症毒素诱导的线粒体改变并改善骨健康。

临床怎么用

  • 对于CKD-MBD患者,需关注线粒体功能障碍和线粒体自噬受损在肾性骨营养不良中的作用。
  • 靶向尿毒症毒素、氧自由基产生和线粒体自噬过程可能成为保护CKD-MBD患者骨健康的新干预策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease-mineral and bone disorder (CKD-MBD) presents with extra-skeletal calcification and renal osteodystrophy (ROD). However, the pathophysiology of ROD remains unclear. Here we examine the hypothesis that stalled mitophagy within osteocytes of CKD-MBD mouse models contributes to bone loss. RNA-seq analysis revealed an altered expression of genes associated with mitophagy and mitochondrial function in tibia of CKD-MBD mice. The expression of mitophagy regulators, p62/SQSTM1, ATG7 and LC3, was inconsistent with functional mitophagy, and in mito-QC reporter mice with ROD, there was a two- to three-fold increase in osteocyte mitolysosomes. To determine if uremic toxins were potentially responsible for these observations, treatment of cultured osteoblasts with uremic toxins revealed increased mitolysosome number and mitochondria with distorted morphology. Membrane potential and oxidative phosphorylation were also decreased, and oxygen-free radical production increased. The altered p62/SQSTM1 and LC3-II expression was consistent with impaired mitophagy machinery, and the effects of uremic toxins were reversible by rapamycin. A causal link between uremic toxins and the development of mitochondrial abnormalities and ROD was established by showing that a mitochondria-targeted antioxidant (MitoQ) and the charcoal adsorbent AST-120 were able to mitigate the uremic toxin-induced mitochondrial changes and improve bone health. Overall, our study shows that impaired clearance of damaged mitochondria may contribute to the ROD phenotype. Targeting uremic toxins, oxygen-free radical production and the mitophagy process may offer novel routes for intervention to preserve bone health in patients with CKD-MBD. This would be timely as our current armamentarium of anti-fracture medications for patients with severe CKD-MBD is limited.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hsu SN, Stephen LA, Phadwal K, et al. Mitochondrial dysfunction and mitophagy blockade contribute to renal osteodystrophy in chronic kidney disease-mineral bone disorder. Kidney Int. 2025. PMID: 39922377. doi:10.1016/j.kint.2025.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。